Docket Management
Docket: 02N-0466 - Randomized Dose Response Study of Dryvax in Children Ages 2 to 5
Comment Number: EC -157

Accepted - Volume 3

Comment Record
Commentor Ms. Judy Lance Date/Time 2002-11-05 10:38:40
Organization Glynn County Health Department
Category Health Professional

Comments for FDA General
Questions
1. General Comments While a safer smallpox vaccine would be appreciated, there is not one at this time. I feel it is worth the risk to conduct this trial because: 1) we do not know where existing supplies of the smallpox virus in the world are (high risk) and the death rate for smallpox in children is high, especially in children 1 y/o or younger. US citizens who are over the age of 30 y/o have already received at least one dose of vaccine and may have some residual immunity, but our children have none.




EC -157